113 related articles for article (PubMed ID: 9934781)
1. Whole-body PET proves superior to CT for staging primary colorectal carcinoma.
Ott DJ
Am J Gastroenterol; 1999 Jan; 94(1):285-6. PubMed ID: 9934781
[No Abstract] [Full Text] [Related]
2. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
3. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
Ito K; Kato T
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):270-7. PubMed ID: 12073633
[TBL] [Abstract][Full Text] [Related]
4. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
5. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
7. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
8. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
9. Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT.
Shin SS; Jeong YY; Min JJ; Kim HR; Chung TW; Kang HK
Abdom Imaging; 2008; 33(3):270-7. PubMed ID: 17610107
[TBL] [Abstract][Full Text] [Related]
10. [Combined functional and morphological imaging with PET/CT systems].
Kaim AH; von Schulthess GK
Praxis (Bern 1994); 2003 Feb; 92(6):225-7. PubMed ID: 12645384
[No Abstract] [Full Text] [Related]
11. Positron emission tomography in colorectal cancer.
Flamen P
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma.
Park IJ; Kim HC; Yu CS; Ryu MH; Chang HM; Kim JH; Ryu JS; Yeo JS; Kim JC
Eur J Surg Oncol; 2006 Nov; 32(9):941-7. PubMed ID: 16843635
[TBL] [Abstract][Full Text] [Related]
13. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
15. Comparison of positron emission tomography and computed tomography in detection of recurrent and metastatic colorectal cancer.
Cohen AM
Ann Surg Oncol; 1997 Dec; 4(8):610. PubMed ID: 9416405
[No Abstract] [Full Text] [Related]
16. Subcutaneous metastases of colorectal cancer detected with PET/CT.
Karyagar S; Karyagar SS; Kece C; Ozdil B
Clin Nucl Med; 2010 Apr; 35(4):267-8. PubMed ID: 20305419
[TBL] [Abstract][Full Text] [Related]
17. Staging recurrent metastatic colorectal carcinoma with PET.
Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
[TBL] [Abstract][Full Text] [Related]
18. PET/CT in Colorectal Cancer.
Schiepers C
J Nucl Med; 2003 Nov; 44(11):1804-5. PubMed ID: 14602863
[No Abstract] [Full Text] [Related]
19. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
20. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
